FDA Approves the First|in|Class Bispecific Antibody for Treatment of ...

EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients ...

With this approval, EPKINLY is the first and only T-cell engaging bispecific antibody administered subcutaneously approved in the U.S. to treat ...

Bispecific Antibody Therapies for Lymphoma - Dana-Farber

Three bispecific antibody therapies have been FDA approved with more on the horizon. These are exciting new medicines that rally the immune ...

Behind the FDA Approval of Zanubrutinib and Obinutuzumab in ...

Christopher Flowers, MD, MS, discussed the phase 2 ROSEWOOD trial, the study that supported the FDA accelerated approval of zanubrutinib and ...

Structure and function of therapeutic antibodies approved by the US ...

Thirty-seven years ago, in 1986, the US FDA approved muromonab CD3 (Orthoclone OKT3), the first monoclonal antibody (mAb) drug, for treatment of organ rejection ...

FDA Grants Fast Track Designation to Novel Bispecific Antibody ...

Phase II/III COMPANION-002 trial shows promise of CTX-009 in combination with paclitaxel for patients with metastatic or locally advanced ...

AbbVie's Epkinly follows Roche's Lunsumio into FL - Fierce Pharma

AbbVie was eager to highlight that Epkinly is now the first bispecific antibody approved to treat both follicular lymphoma and diffuse large B- ...

U.S. FDA Approves TECVAYLI™ (teclistamab-cqyv), the ... - NCODA

TECVAYLI™ is a first-in-class, bispecific T-cell engager antibody that is administered as a subcutaneous treatment.1 This off-the-shelf (or ready to use) ...

MSK ASH 2023 Insights: Promising Results for Bispecific Antibodies ...

The U.S. Food and Drug Administration (FDA) recently approved two CD20xCD3 bispecific antibodies ... first-line treatment in adults with ctDNA ...

Bispecific antibodies: advancing precision oncology - ScienceDirect

Elranatamab (CD3 × BCMA, IgG2a-like, '1+1') is the most recent bsAb approved by the FDA for the treatment of R/R MM, following the results of the MagnetisMM-3 ...

Roche's Bispecific Antibody With Fixed-Duration Treatment Scores ...

The FDA approved Roche Holding AG's (OTC: RHHBY) Columvi (glofitamab-gxbm) for relapsed or refractory (R/R) diffuse large B-cell lymphoma ...

FDA approves Amgen drug for tough-to-treat form of lung cancer

It is the tenth so-called “bispecific” antibody to gain FDA approval in cancer, and the first in small cell lung cancer. The FDA approved ...

FDA approved our new bispecific antibody for treating people with ...

FDA approved our new bispecific antibody for treating people with relapsed or refractory Diffuse Large B-cell Lymphoma / Alexander Hardy, ...

FDA approves EPKINLY® for relapsed or refractory follicular ...

This approval marks a milestone, EPKINLY becomes the first and only T-cell engaging bispecific antibody administered subcutaneously to be ...

Janssen's teclistamab becomes first FDA-approved BCMA bispecific ...

The U.S. FDA cleared teclistamab from ... as the first bispecific antibody for treating ... therapy and triple-class exposed. Median ...

FDA Grants Priority Review to Novel Bispecific Antibody for Multiple ...

Regeneron Pharmaceuticals' linvoseltamab is currently in clinical development to treat adult patients with relapsed/refractory multiple ...

FDA Approves Mosunetuzumab for Relapsed/Refractory Follicular ...

The FDA's decision to approve mosunetuzumab marks the first bispecific antibody approved to treat follicular lymphoma ... class T-cell engaging ...

FDA Approves Epinkly, the First Bispecific Antibody Targeting ...

Abbvie, a pharmaceutical organization, and Genmab, a biotech company, have announced the FDA approval of Epinkly, the first and only T-cell ...

Oncology Nursing Considerations for Bispecific Antibodies in ...

These therapies offer patients and physicians a broader choice of efficacious treatment options. Teclistamab is currently the only FDA-approved bispecific ...

FDA approval of LUNSUMIO™ (mosunetuzumab-axgb) the first-in ...

FDA approval of LUNSUMIO™ (mosunetuzumab-axgb) the first-in-class follicular lymphoma (FL) T-cell engaging bispecific antibody.

FDA Approves Bispecific Antibody Mosunetuzumab-axgb to Treat ...

Mosunetuzumab-axgb is now the first of its class approved by the FDA to treat FL, which is the most common slow-growing form of non-Hodgkin's ...